These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 22777623

  • 1. Brief report: effect of ambrisentan treatment on exercise-induced pulmonary hypertension in systemic sclerosis: a prospective single-center, open-label pilot study.
    Saggar R, Khanna D, Shapiro S, Furst DE, Maranian P, Clements P, Abtin F, Dua S, Belperio J, Saggar R.
    Arthritis Rheum; 2012 Dec; 64(12):4072-7. PubMed ID: 22777623
    [Abstract] [Full Text] [Related]

  • 2. Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
    Klinger JR, Oudiz RJ, Spence R, Despain D, Dufton C.
    Am J Cardiol; 2011 Jul 15; 108(2):302-7. PubMed ID: 21545989
    [Abstract] [Full Text] [Related]

  • 3. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM, Zamanian RT, Damico R, Lechtzin N, Khair R, Kolb TM, Tedford RJ, Hulme OL, Housten T, Pisanello C, Sato T, Pullins EH, Corona-Villalobos CP, Zimmerman SL, Gashouta MA, Minai OA, Torres F, Girgis RE, Chin K, Mathai SC.
    Am J Respir Crit Care Med; 2015 Nov 01; 192(9):1102-10. PubMed ID: 26360334
    [Abstract] [Full Text] [Related]

  • 4. Ambrisentan for pulmonary arterial hypertension: long term effects on clinical status, exercise capacity and haemodynamics.
    D'Alto M, Romeo E, Argiento P, Correra A, Sarubbi B, Scognamiglio G, Grimaldi N, Pignatiello M, Calabrò R, Russo MG.
    Int J Cardiol; 2012 Apr 19; 156(2):244-5. PubMed ID: 22330004
    [No Abstract] [Full Text] [Related]

  • 5. Ambrisentan for sarcoidosis associated pulmonary hypertension.
    Judson MA, Highland KB, Kwon S, Donohue JF, Aris R, Craft N, Burt S, Ford HJ.
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Oct 19; 28(2):139-45. PubMed ID: 22117505
    [Abstract] [Full Text] [Related]

  • 6. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ.
    J Am Coll Cardiol; 2005 Aug 02; 46(3):529-35. PubMed ID: 16053970
    [Abstract] [Full Text] [Related]

  • 7. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
    Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ, Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group.
    Circulation; 2008 Jun 10; 117(23):3010-9. PubMed ID: 18506008
    [Abstract] [Full Text] [Related]

  • 8. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S, Torres F, Feldman J, Keogh A, Allard M, Blair C, Gillies H, Tislow J, Oudiz RJ.
    Respir Med; 2017 May 10; 126():84-92. PubMed ID: 28427554
    [Abstract] [Full Text] [Related]

  • 9. An update on the use of ambrisentan in pulmonary arterial hypertension.
    D'Alto M.
    Ther Adv Respir Dis; 2012 Dec 10; 6(6):331-43. PubMed ID: 22933513
    [Abstract] [Full Text] [Related]

  • 10. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension.
    Halank M, Knudsen L, Seyfarth HJ, Ewert R, Wiedemann B, Kolditz M, Höffken G, Hoeper MM.
    Z Gastroenterol; 2011 Sep 10; 49(9):1258-62. PubMed ID: 21887662
    [Abstract] [Full Text] [Related]

  • 11. Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure.
    Kovacs G, Maier R, Aberer E, Brodmann M, Graninger W, Kqiku X, Scheidl S, Tröster N, Hesse C, Rubin L, Olschewski H.
    Arthritis Rheum; 2012 Apr 10; 64(4):1257-62. PubMed ID: 22127844
    [Abstract] [Full Text] [Related]

  • 12. Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
    Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS.
    J Heart Lung Transplant; 2020 May 10; 39(5):464-472. PubMed ID: 32008947
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y, Jing ZC, Zeng XF, Liu JM, Yu ZX, Zhang GC, Li Y, Wang Y, Ji QS, Zhu P, Wu BX, Zheng Y, Wang PP, Li J.
    BMC Cardiovasc Disord; 2016 Oct 22; 16(1):201. PubMed ID: 27770771
    [Abstract] [Full Text] [Related]

  • 14. Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study.
    Xanthouli P, Uesbeck P, Lorenz HM, Blank N, Eichstaedt CA, Harutyunova S, Egenlauf B, Coghlan JG, Denton CP, Grünig E, Benjamin N.
    Arthritis Res Ther; 2024 Jul 18; 26(1):136. PubMed ID: 39026360
    [Abstract] [Full Text] [Related]

  • 15. Ambrisentan.
    Frampton JE.
    Am J Cardiovasc Drugs; 2011 Aug 01; 11(4):215-26. PubMed ID: 21623643
    [Abstract] [Full Text] [Related]

  • 16. Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study).
    Pan Z, Marra AM, Benjamin N, Eichstaedt CA, Blank N, Bossone E, Cittadini A, Coghlan G, Denton CP, Distler O, Egenlauf B, Fischer C, Harutyunova S, Xanthouli P, Lorenz HM, Grünig E.
    Arthritis Res Ther; 2019 Oct 26; 21(1):217. PubMed ID: 31655622
    [Abstract] [Full Text] [Related]

  • 17. [Effects of ambrisentan in treatment of pulmonary arterial hypertension: a pilot study with 15 patients].
    He J, Wen L, Jiang R, Zhao QH, Wang L, Jiang X, Yan P, Bai L, Jing ZC.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Jun 26; 41(6):493-6. PubMed ID: 24113042
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension.
    Yoshida S, Shirato K, Shimamura R, Iwase T, Aoyagi N, Nakajima H.
    Curr Med Res Opin; 2012 Jun 26; 28(6):1069-76. PubMed ID: 22506623
    [Abstract] [Full Text] [Related]

  • 19. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.
    Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA, Chauhan N, Clements P, Gorn A, Weigt SS, Ross D, Lynch JP, Saggar R.
    Arthritis Rheum; 2010 Dec 26; 62(12):3741-50. PubMed ID: 20722025
    [Abstract] [Full Text] [Related]

  • 20. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
    Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, Jöbsis MM, Loyd JE, Murali S, Frost A, Girgis R, Bourge RC, Ralph DD, Elliott CG, Hill NS, Langleben D, Schilz RJ, McLaughlin VV, Robbins IM, Groves BM, Shapiro S, Medsger TA.
    Ann Intern Med; 2000 Mar 21; 132(6):425-34. PubMed ID: 10733441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.